The CUGBP2 splicing factor regulates an ensemble of branchpoints from perimeter binding sites with implications for autoregulation by Dembowski, JA & Grabowski, PJ
The CUGBP2 Splicing Factor Regulates an Ensemble of
Branchpoints from Perimeter Binding Sites with
Implications for Autoregulation
Jill A. Dembowski, Paula J. Grabowski*
Department of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
Abstract
Alternative pre-mRNA splicing adjusts the transcriptional output of the genome by generating related mRNAs from a single
primary transcript, thereby expanding protein diversity. A fundamental unanswered question is how splicing factors achieve
specificity in the selection of target substrates despite the recognition of information-poor sequence motifs. The CUGBP2
splicing regulator plays a key role in the brain region-specific silencing of the NI exon of the NMDA R1 receptor. However,
the sequence motifs utilized by this factor for specific target exon selection and its role in splicing silencing are not
understood. Here, we use chemical modification footprinting to map the contact sites of CUGBP2 to GU-rich motifs closely
positioned at the boundaries of the branch sites of the NI exon, and we demonstrate a mechanistic role for this specific
arrangement of motifs for the regulation of branchpoint formation. General support for a branch site-perimeter–binding
model is indicated by the identification of a group of novel target exons with a similar configuration of motifs that are
silenced by CUGBP2. These results reveal an autoregulatory role for CUGBP2 as indicated by its direct interaction with
functionally significant RNA motifs surrounding the branch sites upstream of exon 6 of the CUGBP2 transcript itself. The
perimeter-binding model explains how CUGBP2 can effectively embrace the branch site region to achieve the specificity
needed for the selection of exon targets and the fine-tuning of alternative splicing patterns.
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Introduction
Alternative pre-mRNA splicing is prevalent throughout verte-
brate genomes where an individual gene can be diversified into
hundreds or even thousands of related mRNA isoforms [1,2].
Functional consequences of alternative splicing can involve
changes to a subset of the protein’s biochemical properties or
subcellular localization. These are powerful mechanisms used to
regulate protein functions across different cell types, during
development, or in response to extracellular signals [3,4]. One
of the major challenges in postgenome biology is to understand
how alternative splicing, which involves a high degree of inherent
flexibility, can achieve the specificity needed to select the correct
set of target transcripts for regulation.
The spliceosome is the functional context for regulation, since
this is the macromolecular machinery that guides intron removal
and exon joining. It is assembled from the dynamic associations of
five small nuclear ribonucleoprotein particles (snRNPs) and
hundreds of accessory factors [5,6]. Initially, U1 snRNP and
U2AF (U2 snRNP auxiliary factor) recognize the 59 and 39 splice
sites of the exon, respectively, and U2 snRNP base pairs with the
branch site region thereby designating the adenosine to be used as
the branchpoint. The association of U456 tri-snRNP and various
RNA rearrangements then activate the first step of catalysis, which
generates the 59 exon and lariat intron-39 exon intermediate. As
catalysis advances to the second step, the lariat intron is excised
and the 59 and 39 exons are ligated. The overall pattern of exon
inclusion/skipping depends on the ability of the spliceosome to
recognize each splice site signal, which is a reflection of the
inherent strength of the site as well as the regulatory effects of
splicing factors acting from sequence motifs nearby [2,7]. Exon
definition, which involves the interactions of U1 snRNP bound to
the 59 splice site and U2AF bound to the 39 splice site across an
exon is a particularly sensitive mechanism to specify alternative
splicing patterns [8,9].
Two families of RNA binding proteins known to regulate
alternative splicing by direct recognition of RNA sequence motifs
include the arginine-serine rich (SR) and hnRNP splicing factors
[10,11]. SR splicing factors most commonly recognize exonic
splicing enhancers, whereas hnRNP proteins recognize intronic or
exonic splicing silencers and enhancers. These regulatory motifs
are typically short and degenerate making it difficult to reliably
predict the target exons of a splicing factor based upon sequence
inspection alone. CUG Binding Protein 2, or CUGBP2 (also called
NAPOR, CELF-2, ETR-3, or BRUNOL3) is a member of the
larger family of CUGBP and ETR-3-like (CELF) RNA binding
proteins, which have been shown to regulate alternative splicing
through UG-rich motifs in accordance with their tissue-specific
expression patterns [12,13]. CELF proteins have been shown to
play important roles in heart development, whereas their
misregulation has been implicated in the pathogenesis of myotonic
dystrophy [14–16].
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We previously reported a close correlation between the
distribution of protein expression patterns of CUGBP2 (called
NAPOR in the previous study) and splicing patterns of the NI and
CI cassette exons of the NMDAR1 receptor transcript (GRIN1 gene)
in the rat brain [17]. In particular, high levels of CUGBP2 protein in
the forebrain were associated with skipping of the NI exon and
inclusion of the CI exon, and these splicing patterns reversed in the
hindbrain where CUGBP2 was deficient. In vivo splicing reporter
assays confirmed dual functional roles for CUGBP2 as a splicing
silencer of the NI exon and as an enhancer of the CI exon. These
dual roles are thought to be important in directing the brain region-
specific distribution of GRIN1 mRNA isoforms for fine-tuning of
receptor functions at the synapse [17]. Additional splicing factors
have been shown to exhibit dual roles in enhancement and silencing
depending upon the context of the target exons, but these
mechanisms are, at present, poorly understood [18,19].
In this study, we focus on the silencing face of CUGBP2’s dual
character to understand how it recognizes the NI target exon and
the mechanism used for splicing silencing. A variety of intronic UG-
rich motifs can be found within several hundred nucleotides of the
NI and CI exons by sequence inspection, but functionally significant
motifs in these regions have not yet been identified. We initially used
a chemical-based RNA footprinting approach to detect RNA-
protein interactions at nucleotide-level resolution. Here we identify
the direct contact sites of CUGBP2 in the 39 splice site region of the
NI exon, and establish that this arrangement of binding sites plays a
mechanistic role in silencing a group of branch sites in between. We
show the significance of this mechanism by demonstrating its
involvement in the regulation of other skipped exons, most notably
exon 6 of the CUGBP2 transcript itself.
Results
CUGBP2 contacts conserved UGUGU and GU motifs
surrounding the predicted branch site region upstream
from the NI cassette exon
A silencing role for CUGBP2 was shown for the NI exon of the
GRIN1 transcript in a previous study but the mechanism of
silencing was not characterized [17]. To gain insight into the
mechanism, we sought to extend this analysis to identify the
sequence and spatial arrangement of motifs associated with direct
binding of CUGBP2 and silencing of the NI exon. A nitrocellulose
filter binding assay was used initially to locate the RNA region
involved in stable binding by CUGBP2. Bound/total RNA was
plotted as a function of increasing protein concentration and data
were fit to a hyperbola to estimate the dissociation constants (Kd)
for binding to individual RNA transcripts. These RNA substrates
included the NI exon, the NI exon and flanking introns, and the
upstream intron, substrates E5-8, E5-10, and E5-15, respectively
(Figure 1A). CUGBP2 was found to bind to the E5-10 and E5-15
substrates containing the upstream intron region with apparent
dissociation constants in the nanomolar range (96 and 92 nM Kd
values), but not to the E5-8 substrate containing the exon alone
(Figure 1B). Because the downstream intron region is not a
common feature of the high affinity binding substrates, this region,
as well as the exon, must be dispensable for high affinity binding.
To identify the specific nucleotides contacted by CUGBP2, we
next carried out chemical modification footprinting with the E5-10
substrate, which contains the high affinity region identified by filter
binding. CMCT modification at the N3 position of uracil and the
N1 position of guanine causes termination of reverse transcription
initiated at a downstream primer [20]. This chemical was chosen
for footprinting because of the binding preference of human ETR-
3 for (C)UG-rich motifs as indicated by an iterative selection
procedure [13]. A representative footprint of the region upstream
from the NI exon is shown (Figure 1C). These results reveal that a
core (UGUGU) and upstream flanking (GU) motif are protected
by CUGBP2 in a dose-dependent manner. Regions within the NI
exon and in the downstream intron were also subjected to RNA
footprinting with CUGBP2, but no additional binding sites were
detected in agreement with the filter binding experiments.
To verify the specificity of the assay, additional footprinting
reactions were carried out with purified splicing factors U2AF and
PTB. Protected regions were distinct from those observed for
CUGBP2 and consistent with the known RNA binding specificities
of these factors (Figure S1, lanes 1–8). We also demonstrate that
PTB can compete with CUGBP2 for binding to this region of
RNA. That is, when PTB binds to its cognate sites which overlap
with the core UGUGU motif, the pattern of CUGBP2 protection
is lost from not only the core motif but also the upstream GU
motif, suggesting that one CUGBP2 protein simultaneously
contacts both of these sites (Figure S1, lanes 9–12). Notably, the
core and flanking motifs protected by CUGBP2 are located at the
boundaries of the predicted branch site region with the nucleotides
protected by U2AF also within these boundaries. Thus, these
results together with the high sequence conservation of the motifs
(100%) across human, rat, mouse, fruit fly, and chicken genomes,
support their involvement in the mechanism of silencing.
Sequence motifs identified by RNA footprinting are
functionally associated with exon silencing
In order to determine whether nucleotides in contact with
CUGBP2 upstream from the NI exon are necessary for its
silencing role, we generated an in vivo splicing reporter with the NI
exon and its immediate adjacent flanking introns inserted between
b globin exons 1 and 2 (DUPNIwt) (Figure 2A). Mutant derivatives
of this reporter contained site-directed mutations in the GU
dinucleotide and UGUGU core motifs (m1 and m2 motifs,
respectively) as identified by footprinting. A nearby UGUG motif
(m3) was also mutated, since it showed weak protection in the
footprinting assays (data not shown).
Author Summary
Alternative splicing is a precisely controlled process that
determines whether an exon will be included or skipped in
the mature mRNA transcript. Factors that control alterna-
tive splicing bind to RNA sequence motifs in the exon or
flanking introns and guide tissue and developmental
specific splicing events. CUGBP2 is a dual functional
regulator of alternative splicing that can cause inclusion
or skipping of a target exon, depending on the context of
its binding motifs. Previously, the mechanisms of regula-
tion by this protein and the positional significance of its
target motifs have not been characterized. In this study,
the authors dissected the mechanism of exon skipping by
CUGBP2 and demonstrate that a specific configuration of
motifs at the perimeters of a functional reference point are
intimately involved in this event. Furthermore, this
mechanism of regulation is shown to have general
significance because novel CUGBP2 target exons contain
a similar arrangement of motifs. The most interesting of
this group is an exon within the CUGBP2 transcript itself.
This study underscores the importance of a functional
reference point in the specificity of regulation by an
alternative splicing factor and reveals a novel autoregula-
tory role for CUGBP2.
Branchpoint Regulation by Perimeter Binding
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Splicing reporters were co-expressed in the presence and
absence of CUGBP2 in C2C12 mouse myoblast cells or
N18TG2 mouse neuroblastoma cells, which have little or no
endogenous protein as shown by Western blotting (Figure S2). The
change in exon inclusion value, DEI, was then calculated as the
difference between the % exon inclusion6CUGBP2. The DEI
value is used here as a convenient measure of the effectiveness of
CUGBP2 to induce exon skipping (or silencing). While CUGBP2
expression in C2C12 cells induced exon skipping of the wild type
substrate with a DEI value of 233% (Figure 2B, lanes wt)
mutations in all three motifs eliminated silencing entirely as
indicated by a DEI value of 0% (lanes m1,2,3). The double
mutations also showed a significant reduction in the silencing effect
of CUGBP2 (lanes m1,2, m2,3, m1,3). Of this group, combined
mutations at positions m1 and m2 showed the smallest degree of
silencing (DEI 25%), suggesting that these sites are intimately
involved in the mechanism of action. Single mutations also showed
a reduction in silencing indicative of additive effects (lanes m1, m2,
m3). Similar results were observed in N18TG2 cells (Figure 2C).
New to this cell type is higher basal levels of inclusion in the
absence of CUGBP2 and reduced silencing by CUGBP2 on all
substrates tested. This could be the consequence of the differential
expression of splicing factors in these two cell lines. That is, an
enhancer may act on the NI exon in N18TG2 cells and may be
better able to compete with CUGBP2 when its binding sites are
compromised. A good candidate enhancer is FOX because a
perfect match to its enhancer element, (U)GCAUG, is located
near the NI 59 splice site in the downstream intron.
To further investigate the roles of the m1, m2, and m3 motifs for
exon silencing by CUGBP2, we introduced a 39 nucleotide region
containing the three motifs upstream of a constitutive exon in a
different context (Figure 3A). Constitutive exon 3 of the DIP13b
transcript was tested, since its splicing pattern is insensitive to
CUGBP2 regulation, and unlike the NI exon is not under alternative
splicing control. The introduction of the 39 nucleotide region
conferred strong silencing by CUGBP2 (Figure 3B, lanes NIwt; DEI,
Figure 1. CUGBP2 contacts multiple motifs in the intron upstream from the NI cassette exon. (A) Schematic of the NI exon (rectangle)
and flanking introns (lines) are shown with corresponding nucleotide lengths (numbers, top). RNA substrates (E5-8, E5-10, and E5-15) used for filter
binding assays are indicated below. Sequence analyzed by footprinting using primer JBE5-2 (arrow) includes the intron (lower case) and exon
(uppercase) region of the 39 splice site (colon). Shaded sequences represent regions protected from chemical modification by CUGBP2. Individual
adenosines in uppercase represent branchpoints determined by primer extension (see below, Figure 4). (B) Nitrocellulose filter binding analysis. 32P-
labeled RNA substrates from (A) were assembled with purified recombinant CUGBP2 protein and separated into protein bound and unbound
fractions. Representative graphs for each RNA substrate are shown. Inset: Kd values were calculated as the average of three experiments; 6, standard
deviation. (C) RNA footprint analysis. E5-10 RNA was chemically modified with CMCT in the presence or absence of purified CUGBP2 protein. Modified
positions were detected by primer extension (lanes +CMCT), in reference to a sequencing ladder generated from plasmid, E5-10 (lanes T,A,C,G).
Shaded rectangles at right represent protected regions highlighted in the sequence shown in (A). Primer extension of starting material without
modification is shown (lane SM).
doi:10.1371/journal.pgen.1000595.g001
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254%), in contrast to the parent plasmid, which was unregulated by
CUGBP2 (lanes m93wt;DEI,,0%). Single and combined mutations
in the m1, m2, and m3 motifs were also tested in this context (lanes
m1, m2, m3, m1,2, m2,3, m1,3, and m1,2,3). Exon silencing by
CUGBP2 was nearly eliminated when site-directed mutations were
introduced into both the m1 and m2 positions (lanes m1,2; DEI,
26%). Mutations in both the m2 and m3 positions also led to a
significant reduction in silencing (lanes m2,3). Thus, the general
requirement for a pair of proximal CUGBP2motifs, and the additive
effects of the single mutations were verified in this context. This
heterologous reporter was also tested in N18TG2 cells (Figure 3C).
Here, the silencing effects of CUGBP2 were more consistent between
cell lines across all mutations tested. Furthermore, compared to the
NI exon, the DIP13b exon has stronger 59 and 39 splice sites,
therefore mutations had less of an effect on the basal level of exon
inclusion. Taken together, this reporter is a good system to study
isolated effects of CUGBP2 on the m1, m2, and m3 motifs without
indirect effects caused by other splicing factors or weak cis elements.
We also tested the silencing role of a closely related family
member, CUGBP1, on wild type and mutant substrates since it is
Figure 2. The UGUGU core motif and flanking GU dinucleotides are functionally important for CUGBP2 silencing. (A) Schematic of
wild type and mutant versions of the DUPNI splicing reporter. The NI cassette exon (shaded rectangle) and regions of the native flanking introns
(shaded lines) were inserted between b-globin exons bE1 and bE2 downstream of a CMV promoter. Nucleotide lengths in base pairs are indicated
above and below schematic. Sequence shows an expanded view of the NI 39 splice site region with mutations m1, m2, and m3 indicated by
underscores below the shaded regions. Arrows indicate the location of primers used for RT-PCR amplification of exon included and skipped mRNAs.
(B) Splicing reporter expression in C2C12 cells. Splicing reporters with no mutation (wt), with single (m1, m2, m3), or combined (m1,2, m2,3, m1,3,
m1,2,3) mutations were expressed with vector backbone control (2) or with pcDNA4/CUGBP2 expression vector (+). The gel panel is a representative
polyacrylamide gel image with the top band corresponding to the exon included and the bottom band corresponding the exon skipped mRNA. The
bar graph shows the percent exon inclusion as an average of three separate experiments. The change in percent exon inclusion (DEI) as a function of
CUGBP2 expression is shown below the gel panel. Inset: Western blot analysis was used to verify Xpress-tagged CUGBP2 expression; endogenous
hnRNPA1 was a loading control. (C) Experiments were as in (B) except N18TG2 cells were used.
doi:10.1371/journal.pgen.1000595.g002
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expressed in both cell lines tested (Figure S2). CUGBP1 silences the
NI exon (Figure S3A, lanes DUPNI wt) with a dependence on the
same motifs (lanes DUPNI m1,2,3). However, CUGBP1 silencing is
much weaker in the DIPNI context (lanes DIPNI wt, DEI 216
compared to DEI254 for CUGBP2) indicating that additional sites
outside of the transferred region are necessary for strong silencing by
CUGBP1. In support of this, exon 3 of the DIPNIwt reporter is
included .99% of the time in N18TG2 cells (Figure 3C, lanes
NIwt) despite high levels of endogenous CUGBP1 (Figure S2).
Therefore, CUGBP1 shows a weaker silencing role compared to
CUGBP2. As additional controls, we carried out similar experi-
ments with overexpression of PTB or Nova, since both of these
factors are known to silence the NI exon through distinct motifs
(UCUU and YCAY, respectively; Y, pyrimidine). As expected, PTB
and Nova were active in silencing the NI exon in the context of the
DUPNIwt splicing reporter, and these effects were maintained in
the presence of the m1,2,3 triple mutation (Figure S3B). Thus, the
m1, m2, and m3 motifs are specific for silencing by CUGBP2.
CUGBP2 blocks branchpoint formation between core and
flanking interaction motifs
We hypothesized that CUGBP2 may function to silence the NI
exon by blocking branchpoint formation in the upstream intron.
Based on complementarity to U2 snRNA, two candidate branch
Figure 3. CUGBP2 silencing motifs are functionally transferable. (A) A 39 nucleotide region containing the m1, m2, and m3 silencing motifs
from the NI intron (DIPNIwt) was inserted upstream from DIP13b exon 3 (middle exon) in the SIRT1 splicing reporter context. Expression was driven
by the SV40 promoter. Nucleotide lengths in base pairs are indicated. Arrows indicate primers used for RT-PCR amplification; numbers below give
nucleotide lengths contributing to PCR products. Individual or combinations of mutations were introduced at CUGBP2 regulatory sites as in Figure 2.
Sequence of control region (DIPm93wt) corresponds to 39 splice site region of constitutive exon DIP13b exon 3. (B) Splicing reporter plasmids were
cotransfected in C2C12 cells with vector backbone control (2) or with pcDNA4/CUGBP2 expression vector (+). The graph and DEI calculation is as
described for Figure 2. (C) Experiments were as in (B) except N18TG2 cells were used.
doi:10.1371/journal.pgen.1000595.g003
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sites, A1 and A2, are located between the m1 and m2 motifs, and a
third, weaker candidate, A3, resides just downstream between the
m2 and m3 motifs (Figure 4A). As a test of this hypothesis, we
measured branchpoint formation for the DUPNI substrate under
in vitro splicing conditions in the presence and absence of
recombinant CUGBP2. Note that endogenous CUGBP2 levels
are not detectable in Hela nuclear extracts by Western blotting
with the 1H2 antibody, which is highly specific for CUGBP2 [21].
According to our model, the addition of recombinant CUGBP2 to
the extract should bind and preferentially occupy motifs m1 and
m2 on the wild type substrate with the resulting inhibition of one
or more of the branch sites in this neighborhood. The protein can
also bind in an alternate register of lower affinity by contacting a
GU at the m2 site and UGUG at the m3 site. Alternately, one
protein may contact all three sites simultaneously.
Branchpoints were detected by primer extension as for the
experiments in Figure 1C. The results for the wild type substrate
verified the use of the predicted branchpoints with a preference for
A1 and A2, compared to A3 (Figure 4B, lanes 2,3). The A1 and A2
branchpoints satisfied the criteria for ATP dependence (lane 1).
Primer extension of reactions following debranching showed a loss
of stops at A1, A2, and A3 providing confirmation that all three of
these adenosines are used as branchpoints (data not shown).
Notably, branchpoint formation was inhibited when the in vitro
splicing reactions were supplemented with recombinant CUGBP2
(Figure 4B, lane 4). An analysis of the corresponding in vitro
splicing reactions confirmed that CUGBP2 inhibited the forma-
tion of splicing intermediates of these reactions (Figure S4, lanes
wt).
We next examined the effect of the single mutation in motif m1
as a test of whether branchpoint inhibition occurs between core
and flanking motifs. That is, a single mutation in m1 should permit
the binding of CUGBP2 to the remaining intact sites (m2 and m3)
leading to preferential inhibition of branchpoint A3. Indeed, under
conditions in which the m1 site was mutated, branchpoint A3 was
preferentially inhibited as expected for a model involving flanking
interaction motifs (Figure 4B, lanes 7,8). Consistent with this
observation, the corresponding in vitro splicing gel showed that
CUGBP2 inhibited the formation of one lariat intermediate but
not the other (Figure S4, lanes m1). For the single mutant, m3,
which should display the reciprocal pattern of inhibition by
CUGBP2, branchpoints A1 and A2 were preferentially inhibited
relative to A3 (Figure 4B, lanes 11,12). Finally, the triple mutant,
m1,2,3, was tested. Here, the elimination of all three binding
motifs neutralized the inhibitory effects of CUGBP2 on branch-
point formation (lanes 17,18). Again, these results were consistent
with the splicing intermediates of these reactions (Figure S4, lanes
m3 and m1,2,3). Adenovirus major late (Ad1) pre-mRNA was
tested as a control, because Ad1 pre-mRNA lacks CUGBP2 motifs
in the upstream intron. Both the in vitro splicing and branchpoint
formation of Ad1 were unaffected by the addition of recombinant
CUGBP2 (data not shown).
To determine which step before branchpoint formation is
specifically affected by the addition of CUGBP2 to the splicing
reaction, we analyzed complex assembly on the E5-10 RNA
substrate in the presence or absence of recombinant CUGBP2.
We demonstrate that CUGBP2 blocks U2 snRNP association
because CUGBP2 inhibited complex A formation on the wild type
substrate but not on the m1,2,3 mutant substrate (Figure S5A).
The identity of the complex was verified as the U2 snRNP-
containing complex A, since its assembly was inhibited by U2
snRNA cleavage (Figure S5A, S5B). In contrast, parallel samples
assembled in the absence of ATP showed no effect of CUGBP2 on
complex E assembly (Figure S5C).
The results shown above are consistent with a model in which
site-specific binding of CUGBP2 surrounding the branch site
region mediates exon skipping. Because exon definition could
potentially affect branchpoint formation in the upstream intron by
interactions involving U1 snRNP and U2AF across the exon, we
asked whether strengthening the 59 splice site of the NI exon
would antagonize the silencing effect of CUGBP2. For this
purpose, we increased the complementarity of the 59 splice site to
U1 snRNP and tested the ability of CUGBP2 to induce silencing in
vivo. This mutation had no detectable effect on silencing by
CUGBP2 (Figure S6). We also show that U2AF and CUGBP2 can
contact the same RNA at the same time indicating that
branchpoint inhibition occurs after U2AF but before U2 snRNP
binding (Figure S7). This, together with the lack of effect of
CUGBP2 on complex E, which contains U1 snRNP, U2AF, and
SF1, is consistent with a mechanism involving inhibition at a step
subsequent to exon definition. Thus, the inhibitory role of
CUGBP2 is likely to involve direct antagonism of U2 snRNP
binding at the NI branch site region.
Autoregulation of CUGBP2 at the level of alternative
splicing was revealed by a search for additional skipped
exons with a similar arrangement of core and flanking
motifs
A recent publication by Yeo, et al. (2007) used computational
approaches to identify intronic splicing regulatory elements
(ISREs) in the introns upstream and downstream from skipped
exons [22]. One of the ISREs identified was a UGUGUU motif
with the propensity to be found within 400 nucleotides of
conserved skipped exons. The Yeo study identified 168 skipped
exons with a UGUGUU motif in their upstream intron. We
obtained this list for further analysis.
In order to extend our analysis to identify additional exons that
are potentially silenced by CUGBP2, we searched the list of 168
exons for the following sequence features: (1) the presence of
conserved pairs of UGUGU and GU motifs within 100
nucleotides of the 39 splice site of the skipped exon with a spacing
of 10–30 nucleotides between the motifs, and (2) the presence of
potential branch site(s) between the motifs. Because the m1 and
m2 motifs were sufficient to inhibit branchpoints A1 and A2 on the
DUPNIwt substrate, we rationalized that two motifs flanking the
branch site would be sufficient for the prediction of CUGBP2
regulation. Potential branch sites were required to match the
human consensus sequence, YUNAY (Y, pyrimidine; N, any
nucleotide) with one mismatch allowed [23]. From this analysis,
we determined that 48 of the 168 exons (29%) fit these criteria. We
chose 27 exons to test for regulation by CUGBP2.
To analyze the response of these endogenous exons to CUGBP2
overexpression, we optimized a calcium phosphate transfection
method to obtain.90% transfection efficiency in HEK293T cells.
HEK293T cells were chosen for these experiments, since there is
no detectable expression of CUGBP2 (Figure 5A, Western blot).
RNA was harvested from the cells and the test exon region was
amplified by RT-PCR with primers specific for the flanking exons.
Ten predicted exons showed an increase in exon skipping when
CUGBP2 was overexpressed (Figure 5A, panels MAP4_E15,
SORBS1_E5, PPF1BP1_E19, SMARCE1_E4, FOX2_E11, and
CUGBP2_E6; not shown: NFAT_E2, CTBP1_E2, PTER_E3,
and MLLT10_E13). Of the 17 exons that were not affected by
CUGBP2, one was constitutively included and resistant to
CUGBP2, 8 were not expressed in HEK293T cells, and 8 were
always skipped, therefore, CUGBP2 could not induce additional
skipping. Therefore, 10 out of 11 testable exons were regulated by
Branchpoint Regulation by Perimeter Binding
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Figure 4. CUGBP2 blocks branchpoint formation between RNA–protein contact sites. (A) Schematic of the DUPNIwt pre-mRNA used for in
vitro splicing assays. The NI exon and adjacent intron regions are shaded; numbers above schematic indicate nucleotide sizes. Expanded region
shows relative positions of CUGBP2 motifs (m1, m2, m3) and branchpoint adenosines (A1, A2, A3) mapped in these experiments. Branch site
sequences are shown at right; branchpoint adenosine, asterisk; nucleotides matching the consensus YUNAY (Y, pyrimidine; N, any nucleotide),
uppercase; mismatches, lowercase. Alternate registers for CUGBP2 binding are shown schematically in the branch site (BS) perimeter-binding model.
(B) Gel panels show primer extension analysis with primer, JBE5-2. Schematic at right illustrates the termination of reverse transcriptase at
branchpoint positions in the assay. Branchpoint numbers on gel correspond to positions indicated on sequence in (A). A sequencing ladder is shown
for the DUPNIwt plasmid (ladder). For lanes 1–12, splicing reactions containing ATP (+ATP lanes) were incubated for 45 and 60 min with (+) or
without (2) 1.6 mM recombinant CUGBP2. Control reactions lacked ATP. For lanes 13–18, 60 min splicing reactions were used.
doi:10.1371/journal.pgen.1000595.g004
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Figure 5. A motif code for splicing silencing reveals novel endogenous exons that are silenced by CUGBP2. (A) HEK293T cells were
transfected for 36 hours with CUGBP2 protein expression vector (CUGBP2) or vector backbone control (vbb). Exon-included (*) and skipped (**) RT-
PCR products are shown after separation on 2% agarose gels. The gene name and exon number are labeled above each panel. The DEI values are as
follows: SCAMP3_E6, 060; MAPT_E2, 25.360.6; MAP4_E15, 211.763.5; SORBS1_E5, 2861.7; PPF1BP1_E19, 212.362.1; SMARCE1_E4, 221.765.5;
FOX2_E11, 21062; CUGBP1_E6, 24.760.6; CUGBP2_E6, not determined; 6, standard deviation of three separate experiments. Inset: Western blot
confirming CUGBP2 expression (aXpress); total CUGBP2 as detected by 1H2 antibody (aCUGBP2), CUGBP1 and 2 using 3B1 antibody (aCUGBP1,2),
and loading control (ahnRNPA1). Black box: RT-PCR detection of CUGBP2 exon 6 skipped mRNA using primers specific for exon 1 and the exon 5/7
junction (jxn). (B) Model depicting the inhibition of branchpoint formation by the binding of CUGBP2 to flanking interaction sites. Below schematic:
for exons silenced by CUGBP2, the predicted branch sites between the motifs are shown. Branchpoint adenosine (A*); lowercase letters indicate
mismatches to the branch site consensus. Spacing in nucleotides (nt) between the perimeter motifs is shown for all tested exons.
doi:10.1371/journal.pgen.1000595.g005
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CUGBP2 indicating that we have identified a specific code that can
be used to accurately predict CUGBP2 regulation. For all of the
confirmed target exons, the core and flanking motifs were separated
by 14–29 nucleotides, and multiple branch site candidates were
located between the CUGBP2 motifs (Figure 5B). Note that exon 6
of the SCAMP3 transcript, which contains two mismatches to the
GU-rich motif pattern, was insensitive to silencing by CUGBP2.
MAPT_E2 is shown as a positive control, because GRIN1 is not
expressed in HEK293T cells [24].
An interesting observation was the appearance of an exon
skipped product of the CUGBP2 transcript itself, which was
specific for conditions in which CUGBP2 was overexpressed.
However, the primers in this case also amplified mRNA expressed
from transfected CUGBP2, thereby complicating interpretation.
For this reason we designed a downstream primer specific for the
junction between exons 5 and 7, since such a junction primer
should amplify only the skipped product from the endogenous
mRNA. The junction primer was used together with a forward
primer specific for the first exon. The results with the junction
primer clearly showed the accumulation of the exon 6 skipped
version of the endogenous CUGBP2 transcript upon overexpres-
sion of CUGBP2 (Figure 5A, black box). Note that this primer did
not amplify the CUGBP2 protein expression plasmid or mRNA
from transfected CUGBP2 (data not shown). It is also important to
note that although CUGBP2 protein is not detected by Western
blotting, there are low levels of CUGBP2 RNA in HEK293T cells.
This may indicate that trace amounts of the protein are present in
these cells or that the mRNA is translationally repressed.
Furthermore, because there is an enrichment of CUGBP2 protein
in the rat cerebral cortex and a deficiency in the cerebellum [17],
we predicted and confirmed that there would be more skipping of
exon 6 in the cortex (data not shown). To establish the identity of
the exon 6 skipped product, we cut the band out of the gel, cloned
and sequenced it. The cloned product exactly matched the exon
5–7 junction sequence demonstrating its identity as the skipped
product (data not shown).
We also tested an exon in the CUGBP1 transcript that is
homologous to CUGBP2 exon 6 (CUGBP1_E6). Here, there is
one mismatch to the core motif and although CUGBP2 can
silence this exon, the effect is less than other target exons with
perfect matches to the consensus motifs. This suggests that
CUGBP2 regulation can be titrated depending on the sequence
content and binding affinity to target motifs.
CUGBP2 silences its own exon through interaction sites
flanking the branch site region
To determine whether CUGBP2 silences its own exon by a
mechanism similar to that shown for the NI exon, exon 6 and the
adjacent introns of CUGBP2 pre-mRNA were cloned into the
DUP splicing reporter (Figure 6A). In this context, overexpression
of CUGBP2 had a robust silencing effect changing the exon 6
splicing pattern from 100% to 18% inclusion in transfected
HEK293T cells (Figure 6B, lanes Wild type). To address the
functional significance of the CUGBP2 binding sites at the
boundaries of the predicted branch sites, we tested site-directed
mutations in the core (CORE) and downstream (DSM) motifs
(Figure 6A). One perfect match to the branch site consensus (A2)
and two additional candidates with a single mismatch (A1,A3) are
the only plausible branch sites located within 100 nucleotides of
the 39 splice site of exon 6. Mutations in the CORE and DSM
motifs resulted in a reduction of splicing silencing by CUGBP2
(Figure 6B, lanes CORE mt, DSM mt), and these effects were
additive in the double mutant (lanes CORE/DSM mt). These are
similar to the results shown for the NI exon, providing additional
support for the perimeter-binding model. We note that although
mutations did not completely eliminate CUGBP2 regulation of
exon 6, footprinting experiments documented additional contact
points extending from the CORE and DSM motifs suggesting that
alternate binding registers might allow for some residual silencing
(see below). Also note that we tested the possible role of an intronic
UGUGU motif located 70 nucleotides downstream from exon 6.
Mutation of this motif to UAUAU had a negligible effect on
splicing silencing by CUGBP2, ruling out effects across the exon
and further supporting our model (data not shown). Furthermore,
we show that CUGBP1 is also a weak silencer of this exon, but
does not act through the CORE and DSM motifs like CUGBP2
(Figure S3A, lanes CUGBP2_E6).
Finally, we used RNA footprinting to identify CUGBP2 contact
sites in the neighborhood of the predicted branch sites upstream of
exon 6 (Figure 6C and 6D). GU-rich motifs flanking A1, A2, and
A3 were protected by the addition of purified CUGBP2 similar to
that observed above for the NI 39 splice site (Figure 6C, last three
lanes at right). That is, two protected regions at the borders of the
predicted branch sites overlap with the UGUGU core and UG
flanking motifs in agreement with the perimeter-binding model. A
difference in the pattern of protection, however, was the finding
that two sets of motifs on either side of the branch site region
extend outward, indicating variations in the mode of binding
compared to the NI exon.
Discussion
A branch site-perimeter–binding model for alternative
exon silencing
In this study we focused on the silencing face of the dual
functional splicing factor, CUGBP2, to understand how it
recognizes and silences the NI cassette exon of the NMDA R1
receptor. The first hint of how this exon target is recognized was
revealed by chemical modification RNA footprinting of a high
affinity binding region, which showed two contact sites—a core
UGUGU and flanking GU—closely positioned in the neighbor-
hood of the predicted branch sites. These contact sites and a third
weaker footprinting site were shown to modulate alternative
splicing of the NI exon in vivo. Furthermore, the positions of the
branch sites were mapped between the core and flanking motifs.
These branch sites were collectively inhibited by CUGBP2 with a
dependence on the presence of flanking GU-rich binding motifs.
Thus, guilt-by-association places CUGBP2 at the boundaries of
the branch sites it regulates in support of the three-motif
occupancy model illustrated in Figure 4A. The regulation of an
ensemble of branchpoints by a perimeter-type binding model, and
the discovery that an exon in the CUGBP2 transcript is itself
silenced by a similar arrangement of binding motifs, are novel
findings of this study.
We show additional support for this model by identifying novel
skipped exons that are functionally silenced by CUGBP2 based on
database searches for similarities to the configuration of NI
regulatory motifs. These confirmed targets contained the charac-
teristic pattern of candidate branch sites flanked by GU and
UGUGU motifs, which were themselves separated by ,20
nucleotides in the adjacent 39 splice site region (Figure 5). Notably,
exon 6 of the CUGBP2 transcript was the most interesting member
of this group due to the implications for autoregulation. Thus, the
specific arrangement of CUGBP2 bindingmotifs around the branch
sites of the NI exon is a silencing code that can be generalized to
have a functional impact on other skipped exons.
Our results support and extend those of a previous study, which
reported the identification of a UGUGUU motif as an intronic
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Figure 6. CUGBP2 is autoregulated by silencing from exon 6 branch site perimeters. (A) Splicing reporter with sequence showing
predicted branch sites (A1, A2, A3) and CUGBP2 binding motifs (shaded regions). Primers (arrows) used for RT-PCR (bE1 and bE2) or footprinting
analysis (E6) are shown. Mutations in core (CORE) and downstream (DSM) motifs are indicated. (B) Autoregulation of E6 depends upon CUGBP2
binding motifs surrounding the branch site region. Gel panels represent RT-PCR analysis of the wild type or mutant derivatives of the splicing
reporter co-expressed with vector backbone control (lanes vbb) or CUGBP2 protein expression vector (lanes CUGBP2) in HEK293T cells. Percent exon
inclusion values are shown below gel panels. (C) Footprinting analysis of the predicted branch site region upstream of E6 of CUGBP2 pre-mRNA.
Starting material (lane SM), or RNA treated with CMCT in the absence (lane 0) or presence (lanes 3.6, 7.2, 14.4 mM) of CUGBP2 protein. Protected
regions are indicated as shaded boxes at right with extended regions of protection (ext) from the CORE or DSM motifs indicated by arrows. (D) Log
difference of the band intensities of modified nucleotides in the absence or presence of 14.4 mM CUGBP2. Negative values represent regions
protected by CUGBP2. Note that the strength of protection decreases with increasing distance from the primer used for primer extension.
doi:10.1371/journal.pgen.1000595.g006
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splicing regulatory element (U17) enriched within 400 nucleotides
upstream of conserved skipped exons [22]. This previous study
reported the association of the U17 element with exon inclusion in
brain tissue as indicated by microarray analysis. In contrast, our
study shows that the UGUGU core of the U17 element is
generally associated with exon silencing when the motif is paired
with a flanking GU surrounding the functional branch sites. This is
not necessarily a discrepancy, but more likely a reflection of a
mechanism operating on a subset of exons containing a U17-
related element. Here we demonstrate the value of the branch site
as a functional reference point that can be used together with the
precise binding interaction motifs of a splicing factor to
computationally predict new splicing regulatory targets. Our
results are consistent with the types of binding motifs identified for
ETR-3 using a SELEX approach, although the relationship of the
binding motifs to the branch site region and the autoregulatory
role of CUGBP2 were not determined [13]. Furthermore, the
types of motifs identified for Bruno-like proteins in the a-actinin
transcript are in agreement with our results [25].
Branchpoint formation reflects a critical step in the catalysis of
the splicing reaction, but its role in the regulation of alternative
splicing across the transcriptome represents largely uncharted
territory. Only a small number of branchpoints have been
experimentally mapped, however, and there are often multiple
candidate branch sites in the 39 splice site region that match the
consensus sequence [23]. Examples of alternative splicing
regulation through the use of a suboptimal branchpoint include
the calcitonin/calcitonin gene-related peptide exon 4 and
fibroblast growth factor receptor 2 exon IIIc [26–29]. Branch site
selection has also been implicated in the regulation of mutually
exclusive exons of beta tropomyosin and in the processing of
human growth hormone pre-mRNA [30,31].
What advantages would a perimeter-binding model provide for
the control of access to the branch site region? The pre-mRNA
branch site and flanking sequences are sequentially contacted by
several factors during spliceosome assembly [32,33]. The branch
site interacts with the RS domain of U2AF65 bound to the
polypyrimidine tract of the 39 splice site, followed by interactions
with the RS domain of an SR splicing factor bound to an enhancer
element in the adjacent exon [34–36]. Splicing Factor 1 (SF1)
makes direct contacts with the branch site during complex E
assembly [37,38]. In complex A, SAP155 binds to sites flanking
the branch site and replaces SF1 to recruit U2 snRNP [39,40].
Here multiple contact sites may furnish CUGBP2 with the added
stability to inhibit the association of U2 snRNP with the branch
site region and/or may block conformational transitions of the
spliceosome [41]. The perimeter-type binding model described
here is significant in allowing for the coordinate regulation of
multiple branchpoints to control alternative splicing of a cassette
exon. Moreover, the distinctive pattern of RNA motif recognition
by CUGBP2 may facilitate its enhancing roles in other contexts.
CUGBP2 is a modular protein containing three RNA
recognition motifs (RRMs) in which a divergent domain of
unknown function separates RRMs 2–3. The domain structure of
the protein may be geared to facilitate binding of a monomer to a
pair of core and flanking motifs forming a bridge between them as
our model indicates. Alternatively, a single monomer might bind
to all three GU-rich motifs. Both models would limit access to the
branch sites by factors sliding along the RNA from upstream and
downstream directions. Our footprinting results with CUGBP2
are in agreement with previous structural studies showing that a
single RRM can contact ,2–7 nucleotides of its bound RNA
ligand, but additional studies will be required to understand the
topology of binding associated with its silencing function [42–44].
Given the inherent flexibility of RNA binding proteins, it would
not be surprising that breathing motions of CUGBP2 could adjust
the relative conformations of the RRM domains to optimize
recognition specificity in different sequence contexts.
Autoregulation has been shown for a growing number of
splicing factors, including PTB, FOX-2, Nova-1, SRp20, SC-35,
TIA1, and TIAR [45–48]. Here we dissect the mechanism of
CUGBP2 autoregulation. CUGBP2 acts functionally through
motifs surrounding the branch site region to silence exon 6 near
the 59 end of its own transcript. Conceptual translation reveals that
skipping of this exon causes a shift in the reading frame, which
introduces a premature termination codon in the exon 7 region of
the transcript. In this way, the resulting transcript could be
targeted for nonsense-mediated mRNA decay. Conversely,
translation of the exon 6 skipped transcript could generate a
truncated protein ending within RRM2. The advantage of a tight
motif arrangement around the branch site region would be to
dynamically adjust exon 6 inclusion based on fluctuations in the
levels of CUGBP2 protein.
The observation that CUGBP2 can cross regulate exons in the
CUGBP1 and FOX2 transcripts, and that CUGBP1 can silence
CUGBP2 exon 6 to a lesser extent, implicates CUGBP2 in a
network of splicing factor regulation (Figure 5 and Figure S3). We
speculate that this may be important in specifying neural cell
identity and for fine-tuning of neural exon splicing. In the future, it
would be of interest to study the differences in binding specificities
and target exon selection by CUGBP1 and CUGBP2.
The binding of CUGBP2 to the perimeters of the branch sites
allows for sensitive gradations specifying the levels of NI exon
inclusion. Because the peptide region encoded by the NI exon
modulates sensitivity of the NMDA receptor to zinc ions, protons,
and polyamines, such a mechanism would be advantageous for
fine-tuning this modular property of receptor function in different
regions of the brain or during development [49]. The biochemical
functions of NMDA receptors are of fundamental importance in
synaptic plasticity where deficits in this subunit are associated with
altered brain function in the context of Alzheimer’s disease. The
CI cassette exon, which is regulated by the enhancing face of
CUGBP2, encodes a functionally important region of the receptor
involved in membrane trafficking and signaling to the nucleus.
Our study provides the starting point to investigate the broader
roles of CUGBP2 in regulation of the CI cassette and additional
exons throughout the transcriptome. Insights from this study can
also be applied to systematically examine the role of intronic
mutations in the neighborhood of the branch site underlying
mechanisms of human disease.
Methods
Plasmid construction
The mouse CUGBP2 (pcDNA4/NAPOR) and rat PTB
(pcDNA4/PTB) protein expression vectors were described previously
[17]. The Nova-1 protein expression vector was a gift of Robert
Darnell [50] and the CUGBP1 expression vector was a gift of
Thomas Cooper [51]. To generate the DUPNIwt and DUP-
CUGBP2 splicing reporters, the cassette exon and flanking introns
were amplified from rat genomic DNA and inserted between the
ApaI and BglII restriction sites of the DUP4-1 splicing reporter [52].
The DIPm93wt splicing reporter [53] was used to generate DIPNIwt
and mutant derivatives. DIPNIwt was generated by insertion of a 39
base pair fragment containing the 39 splice site region of the NI exon
at position213 base pairs upstream from the test exon. pBSDUPNI
wild type and mutant vectors for in vitro transcription were generated
by PCR amplification from the DUPNIwt or mutant splicing
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reporters and insertion between the HindIII and EcoRI restriction
sites of the pBS- phagemid vector (Stratagene). E5-8, E5-10, and E5-
15 plasmids were generated in a similar manner. Plasmids were
confirmed by restriction digestion and DNA sequencing.
Nitrocellulose filter binding
RNA substrates were 32P-UTP-labeled by in vitro transcription
and used at a final concentration of 1000 cpm/ml (20–100 nM).
RNA was heated at 85uC for 5 min and then cooled to 37uC for
5 min to remove long-range secondary structures. Serial dilutions of
CUGBP2 protein were prepared on ice in binding buffer (50 mM
Tris pH 8.0, 150 mM NaCl, 0.1 mg/ml tRNA, 2 mM DTT, 20
units RNasin (Promega)) in a final volume of 199 ml. Protein samples
were warmed to 37uC for 5 min before adding 1 ml of diluted RNA
(final RNA concentration 100–500 pM). RNA-protein complexes
were assembled in triplicate at 37uC for 30 min before filtration
through 25 mm BA85 filters backed by DE81 filters in a Millipore
1225 vacuum manifold. Filters were separated and dried at room
temperature overnight. The cpm retained on the BA85 filter
corresponded to RNA bound to protein and cpms retained on the
DE81 filter corresponded to free RNA. Bound/total RNA was
plotted as a function of increasing protein concentration using
KaleidaGraph Synergy Software and data were fit to a hyperbola to
estimate the dissociation constant (Kd) according to the equation
bound/total RNA=[CUGBP2]/([CUGBP2]+Kd).
Chemical modification footprinting
RNA-protein complexes were assembled for 30 min at 37uC with
0.18 mMRNA substrate and purified recombinant CUGBP2 protein
in a final volume of 50 ml. Each sample was then combined with an
equal volume of 42 mg/ml 1-cyclohexyl-3-(2-morpholinoethyl)-
carbodiimidemetho-p-toluene-sulfonate (CMCT) and chemical mod-
ification was carried out at 37uC for 7 minutes. Reactions were
terminated by ethanol precipitation. Recovered RNA was treated
with proteinase K followed by phenol chloroform extraction and
ethanol precipitation. Primer extension was carried out with a 5932P-
labeled primer using Superscript II reverse transcriptase (Invitrogen).
Sequencing ladders were generated using Thermo Sequenase Cycle
Sequencing Kit (USB) according to manufacturers protocol. cDNA
was separated on a 10% polyacrylamide gel and gel images were
recorded on a BAS-2500 Phosphorimager (Fujifilm).
Splicing reporter assay
C2C12 and N18TG2 cells were grown in DMEM, 10% (v/v)
fetal bovine serum (FBS). Twenty-four hours prior to transfection
1.56105 C2C12 cells or 26105 N18TG2 cells were seeded on 35-
mm plates to achieve 60–80% confluency. For transient
transfection, 1 mg pcDNA4 His/Max vector backbone or 1 mg
pcDNA4/CUGBP2, pC1-Nova-1, pcDNA4/PTB, or pcDNA3.1/
CUGBP1 expression vector and 0.25 mg splicing reporter were
mixed with 250 ml Opti-MEM followed by addition of an equal
volume of Opti-MEM mixed with 2.5 ml Lipofectamine 2000
(Invitrogen) and incubated at room temperature for 20 min.
Media on cells was replaced with 1.5 ml DMEM, 10% (v/v) FBS
prior to transfection. Total RNA was isolated 36 hours after
transfection using TRIZOL reagent (Invitrogen). Two mg total
RNA was reverse transcribed as described previously [17]. PCR
was carried out in 10 ml reactions containing 1 ml of the reverse
transcription reaction, 0.1 mM of each primer, 2 mM MgCl2,
0.2 mM dNTPs, and 2.5 units Taq DNA polymerase (Promega).
Forward primers were 5932P-labeled. Cycling parameters were
adjusted to give amplification in the linear range. Conditions were
as follows: denaturation 94uC, 1 min, annealing at 60uC, 1 min,
and elongation at 72uC, 1 min for 22 cycles followed by a final
elongation step at 72uC for 10 min. PCR samples were resolved
on 6% polyacrylamide/5 M urea gels. Data were quantified using
a BAS-2500 Phosphorimager system and Image Gauge software.
In vitro splicing and branchpoint analysis
pBSDUPNIwt or mutant derivatives were digested with EcoRI
for in vitro transcription in the presence of a32P-UTP. In vitro
splicing assays were carried out for 45 min or 1 hour as previously
described [54] except MgCl2 was at a final concentration of
2.2 mM. Branchpoints were detected by primer extension from
parallel splicing reactions constituted with unlabeled pre-mRNA
in a reaction containing 200 U MMLV reverse transcriptase
(Invitrogen), 10 mM DTT, 1 mM dNTPs, 16 first strand buffer,
and 50 nM 5932P-labeled primer in a total reaction volume of
20 ml. Reactions were incubated at 37uC for 30 minutes and were
terminated by ethanol precipitation. Samples were resuspended in
6 ml formamide loading buffer and 1/3 of the sample was
separated on an 8% polyacrylamide/7 M urea gel next to a
sequencing ladder. Gel images were recorded on a BAS-2500
Phosphoimager system.
Spliceosome assembly
Spliceosome complexes were assembled on the E5-10 wild type
or mutant RNA in a 10 ml reaction containing 20 mM Hepes,
pH 7.4, 44% Hela nuclear extract, 2.2 mM MgCl2, 60 mM KCl,
1.5 mM ATP, 5 mM creatine phosphate, and 0, 1.6, or 3.2 mM
CUGBP2 at 30uC for 15 minutes. Spliceosome assembly was
stopped by the addition of heparin at a final concentration of
2 mg/ml and incubation for an additional 3 minutes. Half of the
reaction was separated on a 3.75% native polyacrylamide gel cast
in 50 mM tris-glycine buffer and run at 4 watts at 4uC for 4 hours.
Gels were dried under vacuum and visualized by phosphoimager.
For assembly of the ATP-independent E complex, the nuclear
extracts were preincubated at 30uC for 10 minutes to deplete ATP
and complexes were assembled in the absence of ATP or creatine
phosphate for 8 minutes. Oligonucleotide-directed cleavage of U1
and U2 snRNAs was carried out as described previously [55].
Calcium phosphate transfection for analysis of
endogenous mRNA targets of CUGBP2
HEK293T cells were grown in DMEM, 10% (v/v) FBS.
Twenty-four hours prior to transfection, 26105 HEK293T cells
were seeded in 35-mm dishes precoated with poly-L-lysine
(Sigma). Cells were approximately 50% confluent at the time of
transfection. Before transfection, all reagents were brought to
room temperature. For one well, 1.6 ml of 1 mg/ml CUGBP2
protein expression vector or vector backbone was mixed with
16.1 ml 2.5 M CaCl2 by vortexing briefly. Next, 65.8 ml water was
added and the CaCl2-DNA mixture was pipetted over 83.5 ml 26
BBS, pH 7.15 (50 mM N,N-bis(2-hydroxyethyl)-2-aminoethane
sulfonic acid, 280 mM NaCl, 1.5 mM Na2HPO4) and vortexed
for 3 seconds. Mixtures were incubated at room temperature for
10 minutes before 164 ml was added drop wise to each dish. After
transfection, cells were incubated at 3% CO2 for 36 hours prior to
RNA isolation using TRIZOL reagent (Invitrogen). RT-PCR was
carried out as described above with unlabeled primers (Table S1).
PCR samples were resolved on 2% agarose gels and quantified
using Image Gauge software.
Supporting Information
Figure S1 PTB and U2AF65 bind to the polypyrimidine tract
between GU-rich motifs (shaded regions). PTB can effectively
compete with CUGBP2 for binding to the core and upstream
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motifs. Gel: CMCT modification footprint with recombinant PTB
and purified Hela U2AF. Left lane of each set, no protein; gray
wedge, 1.8, 3.6, and 7.2 mM protein added. Right panel:
Competition footprint; left lane, no protein; right lanes, 3.6 mM
CUGBP2; black wedge, 0, 3.6, and 7.2 mM PTB added. PTB
footprint (UCUUCUUCU) is underlined, U2AF footprint (CUU-
CUU) is boxed in schematic.
Found at: doi:10.1371/journal.pgen.1000595.s001 (1.85 MB TIF)
Figure S2 Quantitative Western blot of whole cell lysates
demonstrates that endogenous CUGBP2 levels are low in C2C12
and N18TG2 cells. Whole cell lysates (WCL) were obtained from
90% confluent 10-cm dishes of each cell type as indicated. Western
blot was carried out with antibodies specific for CUGBP2 (1H2),
CUGBP1/2 (3B1), or hnRNPA1 (9H10) as indicated at right. Left
panel is Western blot of recombinant CUGBP2 as a control for
antibody sensitivity and relative protein levels.
Found at: doi:10.1371/journal.pgen.1000595.s002 (0.17 MB TIF)
Figure S3 CUGBP2 regulatory motifs are specific. (A) Splicing
reporters were transfected into C2C12 cells in the presence or
absence of recombinant CUGBP1 as indicated (top) and included
and skipped forms of spliced reporter RNA were assayed by RT-
PCR and separated on a polyacrylamide gel. Percent exon inclusion,
EI (%), and change in percent exon inclusion with CUGBP1
overexpression are indicated below gel panels. The effect of
CUGBP2 overexpression is shown for comparison (CUGBP2). (B)
Splicing reporter assays were carried out as in (A) except Nova and
PTB protein expression vectors were used.
Found at: doi:10.1371/journal.pgen.1000595.s003 (0.76 MB TIF)
Figure S4 Recombinant CUGBP2 inhibits splicing of the intron
upstream of the NI cassette exon in vitro. In vitro splicing
reactions were carried out using the two exon reporters DUPNIwt
and mutant derivatives m1, m3, and m1,2,3. The presence (+) or
absence (2) of ATP or recombinant CUGBP2 (CUGBP2) and the
time of incubation are indicated at top of the gel. The structures of
RNA intermediates and products are indicated at right. Note that
the time dependence of the accumulation of branchpoints mapped
in Figure 4 coincides with the appearance of the intron lariat-39
exon intermediate in the in vitro splicing reactions shown above.
The doublet band in the vicinity of the intron lariat is consistent
with branchpoints at varying distances from the 39 splice site (see
for example, lane 6 from left).
Found at: doi:10.1371/journal.pgen.1000595.s004 (0.98 MB TIF)
Figure S5 Recombinant CUGBP2 inhibits U2 snRNP binding
and complex A but not complex E formation. (A) CUGBP2 inhibits
complex A formation and U2 snRNP binding. Splicing complex
formation was carried out in the presence or absence of ATP,
CUGBP2, or oligonucleotide-directed cleavage of U2 snRNA as
indicated at top on either wild type (wt) or triple mutant (m1,2,3) E5-
10 RNA substrates as indicated below. The position of the ATP
independent complexes E and H are shown at left and the ATP-
dependent complex A is shown at right. (B) Confirmation of
oligonucleotide-directed cleavage of U1 snRNA and U2 snRNA
(indicated at top). Positions of uncleaved U2 snRNA and U1
snRNA are shown at left. (C) CUGBP2 does not inhibit complex E
formation. Splicing complex formation was carried out as in (A)
except ATP was omitted from the reactions.
Found at: doi:10.1371/journal.pgen.1000595.s005 (1.27 MB TIF)
Figure S6 Strengthening the NI cassette exon 59 splice site
complementarity to U1 snRNP does not affect splicing silencing by
CUGBP2. (A) Schematic of mutations made to the 59 splice site to
strengthen U1 snRNP binding (shaded nucleotides). (B) In vivo
splicing assay with overexpression of a vector backbone control
(vbb) or CUGBP2 protein expression vector (CUGBP2). Graph
shows % exon inclusion values; error bars, standard deviations.
Found at: doi:10.1371/journal.pgen.1000595.s006 (0.15 MB TIF)
Figure S7 CUGBP2 and U2AF can bind to the same RNA at the
same time. Increasing amounts of recombinant wild type or mutant
CUGBP2 containing only RRMs 1 and 2 (RRM1_2) or RRMs 2
and 3 (RRM2_3) were bound to E5-10 RNA in the presence or
absence of Hela purified U2AF. Protein concentrations are labeled
on the top of the gel and free RNA and RNA-protein complexes are
labeled at right.
Found at: doi:10.1371/journal.pgen.1000595.s007 (0.70 MB TIF)
Table S1 Primers used for analysis of endogenous target exons
shown in Figure 5.
Found at: doi:10.1371/journal.pgen.1000595.s008 (0.03 MB
XLS)
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